Alps Advisors Inc. lessened its holdings in shares of AnaptysBio Inc (NASDAQ:ANAB) by 4.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,927 shares of the biotechnology company’s stock after selling 2,636 shares during the quarter. Alps Advisors Inc.’s holdings in AnaptysBio were worth $1,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of ANAB. Aperio Group LLC purchased a new position in shares of AnaptysBio during the 2nd quarter worth $45,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of AnaptysBio by 42.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,851 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 553 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in shares of AnaptysBio during the 1st quarter valued at $110,000. Bank of Montreal Can purchased a new position in shares of AnaptysBio during the 2nd quarter valued at $115,000. Finally, Whittier Trust Co. lifted its stake in shares of AnaptysBio by 35.0% during the 3rd quarter. Whittier Trust Co. now owns 5,085 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,317 shares in the last quarter.

ANAB has been the topic of a number of analyst reports. Stifel Nicolaus restated a “hold” rating on shares of AnaptysBio in a research note on Monday, September 30th. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Wednesday, October 30th. Jefferies Financial Group cut shares of AnaptysBio from a “buy” rating to a “hold” rating and set a $12.00 target price on the stock. in a research note on Friday. JPMorgan Chase & Co. cut shares of AnaptysBio from an “overweight” rating to an “underweight” rating and lowered their target price for the company from $109.00 to $17.00 in a research note on Friday. Finally, SunTrust Banks cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Hold” and a consensus price target of $75.11.

Shares of ANAB stock opened at $10.18 on Friday. The stock has a market cap of $1.05 billion, a P/E ratio of -4.07 and a beta of 1.50. AnaptysBio Inc has a 52 week low of $10.00 and a 52 week high of $83.10. The company’s fifty day simple moving average is $36.21 and its two-hundred day simple moving average is $53.30.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Friday, November 8th. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.06). During the same quarter in the prior year, the company posted ($0.66) EPS. On average, research analysts forecast that AnaptysBio Inc will post -4.02 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

See Also: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.